Inhalation Anaesthesia Market Report and Forecast 2025-2034
Description
The global inhalation anaesthesia market size reached a value of more than USD 1.25 Billion in 2024 driven by the increasing prevalence of chronic diseases and medical device manufacturers across the globe. The market is further estimated to grow at a CAGR of 9.40% in the forecast period of 2025-2034.
Global Inhalation Anaesthesia Market Overview
Inhalation anaesthesia is a clinical procedure used in medical practice to make patients unconscious or numb during surgery. In this method, anaesthetic agents are delivered as gases or volatile agents to the patient via a face mask, or an endotracheal tube placed in the respiratory tract. Some of these anaesthetic agents include nitrous oxide, sevoflurane, isoflurane, and desflurane. When administered in measured proportions, it provides the ideal level of anaesthesia and pain relief without compromising the body’s basic functions. The sedative agents are transported through the respiratory system, lungs, and circulatory system, affecting the patient’s brain and central nervous system. As the incidence rate of chronic diseases that may require surgeries rise, the demand for inhalational anesthesia is likely to increase in coming years.
Global Inhalation Anaesthesia Market Growth Drivers
Increasing Prevalence of Surgical Procedures Fuels Market Growth
The market for surgical procedures is growing due to the increasing application of inhalation anesthesia in from road accidents and emergencies. Global healthcare faces challenges due to the increasing incidence of diseases such as cancer, respiratory illnesses, and gastrointestinal issues. Chronic diseases like cancer, infectious diseases, and genetic disorders are also rising globally. The American Cancer Society reports that cancer contributes significantly to morbidity and mortality, with an estimated about 1,958,310, new cases and 609,820 cancer-related deaths in 2023. This, coupled with the increasing prevalence of chronic diseases, drives market growth for inhalation anesthesia.
Increased Geriatric Population Promoting the Inhalation Anaesthesia Market
The global geriatric population is expected to drive the growth of inhalation anaesthesia due to their high susceptibility to degenerative and chronic diseases. Elderly patients, particularly those with cardiovascular, neurological, respiratory, or degenerative conditions, are more likely to require surgeries and therapeutics. The discomfort of injecting anaesthesia through intravenous routes for elderly patients is a significant factor, which will continue to influence the consistent demand for inhalation anaesthesia in the coming years.
Global Inhalation Anaesthesia Market Trends
Improvement in Ambulatory Surgical Centers
Ambulatory surgical centers (ASCs) play an essential role in the healthcare system by providing flexible and effective outpatient surgeries. They offer low-cost therapies, shorter hospitalizations, and decreased susceptibilities to infections. One of the most preferred techniques by patients receiving treatment as ASC is inhalation anaesthesia due to its simplicity and rapid onset. This integration between ASCs and inhalation anaesthesia helps patients by giving comfortable treatments, and shorter recovery times that do not interfere with their daily activities.
Role of End-Tidal (ET) Control Software in Advancing Anesthesia Delivery
Market players in inhalation anaesthesia are improving their offerings by incorporating new technologies such as end-tidal control software into their products. The Aisys CS2 Anaesthesia Delivery System is one major examples of more advanced system that uses the latest software to track anaesthesia gases during various surgeries and give patients ideal care. With this technology, surgeries are safer and more comfortable for the patients. This new system in anaesthesia is designed to improve the quality of patient care and set future trends in surgical operations.
Technological Advancements
The advancement of innovative and efficient anaesthesia delivery systems like the Sedaconda has continued in recent years. These systems are developed particularly for intensive care and include features like tracking and control, which help healthcare practitioners to provide anaesthesia with better efficiency and safety. This trend shows a focus on improving patient care delivery as well as embracing environmental stewardship.
AI and Machine Learning
Artificial intelligence and machine learning are increasingly being integrated in anaesthesia delivery systems to improve accuracy and patient safety. When applied to inhalation anaesthesia, AI and ML can detect and manage anaesthesia levels in real time, thus improving the efficacy, safety, and outcomes of the procedure. Closed-loop systems that control the administration of drugs based on the patient’s physiological condition are being used more often. This integration represents a progressive step in enhancing the efficacy and safety of provision.
Global Inhalation Anaesthesia Market Segmentation
The EMR’s report titled “Inhalation Anaesthesia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Based on Drug Type Sevoflurane to Hold a Substantial Market Share
Based on drug type, the market is segmented into sevoflurane, desflurane, isoflurane, and halothane. Among these, the increasing use of sevoflurane, owing to several benefits including a pleasant odor, rapid induction, reduced postoperative nausea, and minimal cardiac toxicity are driving its market share. Patients with difficult airways or severe bronchospastic disease are increasingly using sevoflurane due to its reduced irritation to mucous membranes and faster recovery. The drug is also used in both inpatient and outpatient surgeries, and its excellent safety record makes it suitable for both adults and pediatric patients. The increasing approvals of sevoflurane by the Food and Drug Administration (FDA) are expected to further stimulate the market development.
Market Breakup Based on Application Set to Witness Market Growth
The global inhalation anaesthesia market, based on applications is divided into inductive and maintenance. Maintenance anaesthesia is expected to dominate the market because it ensures patients remain unconscious during operations. Maintenance anaesthesia also involves administering anaesthetics in progressively regulated dosages, making it useful for long procedures. This constant demand drives companies to upgrade delivery systems for maintenance, focusing on patient safety and improving technologies for tracking anaesthesia depth and reducing complications.
Global Inhalation Anaesthesia Market Analysis by Region
The market report reveals regional trends in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to dominate due to rising surgery rates and hospital requirements. Asia Pacific region is experiencing significant growth due to increasing disease prevalence and the elderly population. Inhalation anaesthetic drugs like Sevoflurane and Desflurane are in high demand due to their fast induction and recovery. The market is estimated to witness revenue growth, especially in response to the growing geriatric population in China.
Leading Players in the Global Inhalation Anaesthesia Market
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Halocarbon Life Sciences, LLC.
Established in 1950 and based in Atlanta, Georgia, the key products from this company includes isoflurane USP and Sevoflurane USP, both of which are widely used in human and veterinary medicine. Isoflurane USP is favored for its rapid onset and recovery times, making it a reliable choice for various surgical procedures.
Baxter International Inc.
It is a U.S. based company founded in 1931. This company is a leader in the inhalation anaesthesia market. Their product lineup includes Suprane (Desflurane), Forane (Isoflurane), and Sevoflurane.
AbbVie Inc.
Founded in 2013 and based in North Chicago, Illinois, the company provides Sevoflurane (marketed as Ultane) as its primary inhalation anaesthetic. Ultane is widely used for its quick induction and emergence properties, making it suitable for both pediatric and adult patients.
Sandoz AG
The company was founded in Basel, Switzerland in 1886. The company offers a range of inhalation anaesthetics including Desflurane, Sevoflurane, and Isoflurane. It launched Desflurane as a generic version of Suprane, providing a cost-effective option for maintaining anaesthesia during surgeries.
Other companies include Piramal Enterprises Ltd., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, and Troikaa Pharmaceuticals Ltd.
Kindly note that this only represents a partial list of companies and the complete list has been in the report.
Key Questions Answered in the Inhalation Anaesthesia Market Report
Global Inhalation Anaesthesia Market Overview
Inhalation anaesthesia is a clinical procedure used in medical practice to make patients unconscious or numb during surgery. In this method, anaesthetic agents are delivered as gases or volatile agents to the patient via a face mask, or an endotracheal tube placed in the respiratory tract. Some of these anaesthetic agents include nitrous oxide, sevoflurane, isoflurane, and desflurane. When administered in measured proportions, it provides the ideal level of anaesthesia and pain relief without compromising the body’s basic functions. The sedative agents are transported through the respiratory system, lungs, and circulatory system, affecting the patient’s brain and central nervous system. As the incidence rate of chronic diseases that may require surgeries rise, the demand for inhalational anesthesia is likely to increase in coming years.
Global Inhalation Anaesthesia Market Growth Drivers
Increasing Prevalence of Surgical Procedures Fuels Market Growth
The market for surgical procedures is growing due to the increasing application of inhalation anesthesia in from road accidents and emergencies. Global healthcare faces challenges due to the increasing incidence of diseases such as cancer, respiratory illnesses, and gastrointestinal issues. Chronic diseases like cancer, infectious diseases, and genetic disorders are also rising globally. The American Cancer Society reports that cancer contributes significantly to morbidity and mortality, with an estimated about 1,958,310, new cases and 609,820 cancer-related deaths in 2023. This, coupled with the increasing prevalence of chronic diseases, drives market growth for inhalation anesthesia.
Increased Geriatric Population Promoting the Inhalation Anaesthesia Market
The global geriatric population is expected to drive the growth of inhalation anaesthesia due to their high susceptibility to degenerative and chronic diseases. Elderly patients, particularly those with cardiovascular, neurological, respiratory, or degenerative conditions, are more likely to require surgeries and therapeutics. The discomfort of injecting anaesthesia through intravenous routes for elderly patients is a significant factor, which will continue to influence the consistent demand for inhalation anaesthesia in the coming years.
Global Inhalation Anaesthesia Market Trends
Improvement in Ambulatory Surgical Centers
Ambulatory surgical centers (ASCs) play an essential role in the healthcare system by providing flexible and effective outpatient surgeries. They offer low-cost therapies, shorter hospitalizations, and decreased susceptibilities to infections. One of the most preferred techniques by patients receiving treatment as ASC is inhalation anaesthesia due to its simplicity and rapid onset. This integration between ASCs and inhalation anaesthesia helps patients by giving comfortable treatments, and shorter recovery times that do not interfere with their daily activities.
Role of End-Tidal (ET) Control Software in Advancing Anesthesia Delivery
Market players in inhalation anaesthesia are improving their offerings by incorporating new technologies such as end-tidal control software into their products. The Aisys CS2 Anaesthesia Delivery System is one major examples of more advanced system that uses the latest software to track anaesthesia gases during various surgeries and give patients ideal care. With this technology, surgeries are safer and more comfortable for the patients. This new system in anaesthesia is designed to improve the quality of patient care and set future trends in surgical operations.
Technological Advancements
The advancement of innovative and efficient anaesthesia delivery systems like the Sedaconda has continued in recent years. These systems are developed particularly for intensive care and include features like tracking and control, which help healthcare practitioners to provide anaesthesia with better efficiency and safety. This trend shows a focus on improving patient care delivery as well as embracing environmental stewardship.
AI and Machine Learning
Artificial intelligence and machine learning are increasingly being integrated in anaesthesia delivery systems to improve accuracy and patient safety. When applied to inhalation anaesthesia, AI and ML can detect and manage anaesthesia levels in real time, thus improving the efficacy, safety, and outcomes of the procedure. Closed-loop systems that control the administration of drugs based on the patient’s physiological condition are being used more often. This integration represents a progressive step in enhancing the efficacy and safety of provision.
Global Inhalation Anaesthesia Market Segmentation
The EMR’s report titled “Inhalation Anaesthesia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
- Sevoflurane
- Desflurane
- Isoflurane
- Halothane
- Induction
- Maintenance
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Based on Drug Type Sevoflurane to Hold a Substantial Market Share
Based on drug type, the market is segmented into sevoflurane, desflurane, isoflurane, and halothane. Among these, the increasing use of sevoflurane, owing to several benefits including a pleasant odor, rapid induction, reduced postoperative nausea, and minimal cardiac toxicity are driving its market share. Patients with difficult airways or severe bronchospastic disease are increasingly using sevoflurane due to its reduced irritation to mucous membranes and faster recovery. The drug is also used in both inpatient and outpatient surgeries, and its excellent safety record makes it suitable for both adults and pediatric patients. The increasing approvals of sevoflurane by the Food and Drug Administration (FDA) are expected to further stimulate the market development.
Market Breakup Based on Application Set to Witness Market Growth
The global inhalation anaesthesia market, based on applications is divided into inductive and maintenance. Maintenance anaesthesia is expected to dominate the market because it ensures patients remain unconscious during operations. Maintenance anaesthesia also involves administering anaesthetics in progressively regulated dosages, making it useful for long procedures. This constant demand drives companies to upgrade delivery systems for maintenance, focusing on patient safety and improving technologies for tracking anaesthesia depth and reducing complications.
Global Inhalation Anaesthesia Market Analysis by Region
The market report reveals regional trends in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to dominate due to rising surgery rates and hospital requirements. Asia Pacific region is experiencing significant growth due to increasing disease prevalence and the elderly population. Inhalation anaesthetic drugs like Sevoflurane and Desflurane are in high demand due to their fast induction and recovery. The market is estimated to witness revenue growth, especially in response to the growing geriatric population in China.
Leading Players in the Global Inhalation Anaesthesia Market
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Halocarbon Life Sciences, LLC.
Established in 1950 and based in Atlanta, Georgia, the key products from this company includes isoflurane USP and Sevoflurane USP, both of which are widely used in human and veterinary medicine. Isoflurane USP is favored for its rapid onset and recovery times, making it a reliable choice for various surgical procedures.
Baxter International Inc.
It is a U.S. based company founded in 1931. This company is a leader in the inhalation anaesthesia market. Their product lineup includes Suprane (Desflurane), Forane (Isoflurane), and Sevoflurane.
AbbVie Inc.
Founded in 2013 and based in North Chicago, Illinois, the company provides Sevoflurane (marketed as Ultane) as its primary inhalation anaesthetic. Ultane is widely used for its quick induction and emergence properties, making it suitable for both pediatric and adult patients.
Sandoz AG
The company was founded in Basel, Switzerland in 1886. The company offers a range of inhalation anaesthetics including Desflurane, Sevoflurane, and Isoflurane. It launched Desflurane as a generic version of Suprane, providing a cost-effective option for maintaining anaesthesia during surgeries.
Other companies include Piramal Enterprises Ltd., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, and Troikaa Pharmaceuticals Ltd.
Kindly note that this only represents a partial list of companies and the complete list has been in the report.
Key Questions Answered in the Inhalation Anaesthesia Market Report
- What was the global inhalation anaesthesia market value in 2024?
- What is the global inhalation anaesthesia market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on drug type?
- What is the market breakup based on application?
- What are the major factors aiding the global inhalation anaesthesia market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global inhalation anaesthesia market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the inhalation anaesthesia market?
- What are the current unmet needs and challenges?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
- What is the current market size of Sevoflurane in the global inhalation anaesthesia market?
- Who are the leading manufacturers and suppliers of Sevoflurane?
- What regulatory approvals are affecting the market dynamics of Desflurane?
- What are the potential side effects and concerns associated with Desflurane use?
- What are the competitive advantages of Isoflurane over other inhalation anaesthesia?
- How do the induction times of various inhalation anaesthetics compare?
- What percentage of inhalation anaesthetics is used for maintenance during surgeries?
- What are the emerging trends in the maintenance application of the inhalation anaesthesia market?
- What is the current market size and growth rate of inhalation anaesthesia in North America?
- How is the market affected by the healthcare infrastructure in different European countries?
- Which countries in the Asia Pacific are showing the highest demand for inhalation anaesthetics?
- What are the key market drivers and restraints in Latin America?
- How is the healthcare sector evolving in the Middle East and Africa about the inhalation anaesthesia market?
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Inhalation Anaesthesia Market Overview
- 3.1 Global Inhalation Anaesthesia Market Historical Value (2018-2024)
- 3.2 Global Inhalation Anaesthesia Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Inhalation Anaesthesia Market Landscape*
- 5.1 Global Inhalation Anaesthesia: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Inhalation Anaesthesia: Product Landscape
- 5.2.1 Analysis by Drug Type
- 5.2.2 Analysis by Application
- 6 Global Inhalation Anaesthesia Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Inhalation Anaesthesia Market Segmentation (218-2034)
- 7.1 Global Inhalation Anaesthesia Market (2018-2034) by Drug Type
- 7.1.1 Market Overview
- 7.1.2 Sevoflurane
- 7.1.3 Desflurane
- 7.1.4 Isoflurane
- 7.1.5 Halothane
- 7.2 Global Inhalation Anaesthesia Market (2018-2034) by Application
- 7.2.1 Market Overview
- 7.2.2 Induction
- 7.2.3 Maintenance
- 7.3 Global Inhalation Anaesthesia Market (2018-2034) by Region
- 7.3.1 Market Overview
- 7.3.2 North America
- 7.3.3 Europe
- 7.3.4 Asia Pacific
- 7.3.5 Latin America
- 7.3.6 Middle East and Africa
- 8 North America Inhalation Anaesthesia Market (218-2034)
- 8.1 North America Inhalation Anaesthesia Market (2018-2034) by Drug Type
- 8.1.1 Market Overview
- 8.1.2 Sevoflurane
- 8.1.3 Desflurane
- 8.1.4 Isoflurane
- 8.1.5 Halothane
- 8.2 North America Inhalation Anaesthesia Market (2018-2034) by Application
- 8.2.1 Market Overview
- 8.2.2 Induction
- 8.2.3 Maintenance
- 8.3 North America Inhalation Anaesthesia Market (2018-2034) by Country
- 8.3.1 United States of America
- 8.3.2 Canada
- 9 Europe Inhalation Anaesthesia Market (218-2034)
- 9.1 Europe Inhalation Anaesthesia Market (2018-2034) by Drug Type
- 9.1.1 Market Overview
- 9.1.2 Sevoflurane
- 9.1.3 Desflurane
- 9.1.4 Isoflurane
- 9.1.5 Halothane
- 9.2 Europe Inhalation Anaesthesia Market (2018-2034) by Application
- 9.2.1 Market Overview
- 9.2.2 Induction
- 9.2.3 Maintenance
- 9.3 Europe Inhalation Anaesthesia Market (2018-2034) by Country
- 9.3.1 United Kingdom
- 9.3.2 Germany
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Others
- 10 Asia Pacific Inhalation Anaesthesia Market (218-2034)
- 10.1 Asia Pacific Inhalation Anaesthesia Market (2018-2034) by Drug Type
- 10.1.1 Market Overview
- 10.1.2 Sevoflurane
- 10.1.3 Desflurane
- 10.1.4 Isoflurane
- 10.1.5 Halothane
- 10.2 Asia Pacific Inhalation Anaesthesia Market (2018-2034) by Application
- 10.2.1 Market Overview
- 10.2.2 Induction
- 10.2.3 Maintenance
- 10.3 Asia Pacific Inhalation Anaesthesia Market (2018-2034) by Country
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 ASEAN
- 10.3.5 Australia
- 10.3.6 Others
- 11 Latin America Inhalation Anaesthesia Market (218-2034)
- 11.1 Latin America Inhalation Anaesthesia Market (2018-2034) by Drug Type
- 11.1.1 Market Overview
- 11.1.2 Sevoflurane
- 11.1.3 Desflurane
- 11.1.4 Isoflurane
- 11.1.5 Halothane
- 11.2 Latin America Inhalation Anaesthesia Market (2018-2034) by Application
- 11.2.1 Market Overview
- 11.2.2 Induction
- 11.2.3 Maintenance
- 11.3 Latin America Inhalation Anaesthesia Market (2018-2034) by Country
- 11.3.1 Brazil
- 11.3.2 Argentina
- 11.3.3 Mexico
- 11.3.4 Others
- 12 Middle East and Africa Inhalation Anaesthesia Market (218-2034)
- 12.1 Middle East and Africa Inhalation Anaesthesia Market (2018-2034) by Drug Type
- 12.1.1 Market Overview
- 12.1.2 Sevoflurane
- 12.1.3 Desflurane
- 12.1.4 Isoflurane
- 12.1.5 Halothane
- 12.2 Middle East and Africa Inhalation Anaesthesia Market (2018-2034) by Application
- 12.2.1 Market Overview
- 12.2.2 Induction
- 12.2.3 Maintenance
- 12.3 Middle East and Africa Inhalation Anaesthesia Market (2018-2034) by Country
- 12.3.1 Saudi Arabia
- 12.3.2 United Arab Emirates
- 12.3.3 Nigeria
- 12.3.4 South Africa
- 12.3.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Clinical Trial Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Grant Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Product
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Type of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Type of Partnership
- 18.3 Analysis by Leading Players
- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis, By Region (Top 5 Companies)
- 19.1.1 Market Share Analysis: Global
- 19.1.2 Market Share Analysis: North America
- 19.1.3 Market Share Analysis: Europe
- 19.1.4 Market Share Analysis: Asia Pacific
- 19.1.5 Market Share Analysis: Others
- 19.2 Halocarbon Life Sciences, LLC .
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Mergers and Acquisitions
- 19.2.5 Certifications
- 19.3 Baxter International Inc
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Mergers and Acquisitions
- 19.3.5 Certifications
- 19.4 AbbVie Inc .
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Mergers and Acquisitions
- 19.4.5 Certifications
- 19.5 Sandoz AG
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Mergers and Acquisitions
- 19.5.5 Certifications
- 19.6 Piramal Enterprises Ltd .
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Mergers and Acquisitions
- 19.6.5 Certifications
- 19.7 Dechra Pharmaceuticals PLC
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Mergers and Acquisitions
- 19.7.5 Certifications
- 19.8 Fresenius Kabi AG
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Mergers and Acquisitions
- 19.8.5 Certifications
- 19.9 Hikma Pharmaceuticals PLC
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Mergers and Acquisitions
- 19.9.5 Certifications
- 19.10 Jiangsu Hengrui Medicine Co. Ltd
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Mergers and Acquisitions
- 19.10.5 Certifications
- 19.11 Lunan Pharmaceutical Group Co. Ltd
- 19.11.1 Financial Analysis
- 19.11.2 Product Portfolio
- 19.11.3 Demographic Reach and Achievements
- 19.11.4 Mergers and Acquisitions
- 19.11.5 Certifications
- 19.12 Merck KGaA
- 19.12.1 Financial Analysis
- 19.12.2 Product Portfolio
- 19.12.3 Demographic
- 19.12.4 Mergers and Acquisitions
- 19.12.5 Certifications
- 19.13 Troikaa Pharmaceuticals Ltd
- 19.13.1 Financial Analysis
- 19.13.2 Product Portfolio
- 19.13.3 Demographic Reach and Achievements
- 19.13.4 Mergers and Acquisitions
- 19.13.5 Certifications
- 20 Inhalation Anaesthesia Market – Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
